Announcement
16 Oct 2025
In October 2025, the United States government announced an agreement with EMD Serono to implement most-favored-nation drug pricing for American patients. The agreement secured an exemption for EMD Serono from prospective tariffs on the pharmaceutical imports.
Source
Sign in to access
Number of interventions
3
0 certainly harmful
3 likely harmful
0 liberalising
List of interventions
Implementation date
16 Oct 2025
Revocation date:
No revocation date
Updated: 17 Oct 2025
Local operations incentive
In force
Recent update from 17 Oct 2025:
On 16 October 2025, the U.S. Administration announced an agreement with EMD Serono. Under the agreement, EMD Serono will be exempt from Section 232 tariffs on pharmaceutical products, in exchange f...
Sign in to see more
Implementation date
No implementation date
Revocation date:
No revocation date
Updated: 17 Oct 2025
Tax or social insurance relief
Recent update from 17 Oct 2025:
On 16 October 2025, the U.S. Administration announced reaching an agreement with EMD Serono. Under the agreement, EMD Serono will be exempt from future Section 232 tariffs on pharmaceutical product...
Sign in to see more
Updated: 17 Oct 2025
Import tariff
Recent update from 17 Oct 2025:
On 16 October 2025, the United States of America announced an agreement with EMD Serono, exempting the company from the future Section 232 pharmaceutical tariffs. In exchange for this exemption, EM...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.